Sarantis Worldwide


Visit our group site

Sarantis Group| English

Or choose a location

2025 Financial Calendar

4 FEBRUARY 2025

SARANTIS S.A., in its practice of providing accurate and timely information to investors and in accordance with the article 4.1.2 of the Athens Stock Exchange Regulation, announces its Financial Calendar for 2025:

  • Wednesday 12 March 2025: 2024 Annual Financial Results release and Publication of Annual Financial Report 2024
  • Thursday 13 March 2025: FY 2024 Annual Analysts’ and Investors’ conference call
  • Thursday 27 March 2025: ESG Targets and Roadmap communication via conference call
  • Monday 28 April 2025: Annual General Meeting of Shareholders
  • Friday 2 May 2025: Dividend cut-off date
  • Monday 5 May 2025: Dividend beneficiaries - Record date
  • Tuesday 6 May 2025: 1st Quarter 2025 Trading Update
  • Friday 9 May 2025: Dividend payment date
  • Tuesday 9 September 2025: H1 2025 Financial Results release
  • Wednesday 10 September 2025: H1 2025 Analysts’ and Investors’ conference call
  • Thursday 23 October 2025: Nine-month 2025 Trading Update

The distribution of dividend and the abovementioned relevant dates are subject to approval by the Annual General Meeting of the Shareholders.

The Company would like to clarify that the annual and half-year financial results will be released following the Athens Stock Exchange market close, while Q1 and 9m trading updates will be released before market opening, at the website of Athens Exchange www.helex.gr and at the Company's website www.sarantisgroup.com.

The Company reserves the right to alter the above dates after timely informing the investment community of the amendment hereof, as defined in the Athens Exchange Regulation.

2025 Financial Calendar Update (239.0KB)

Sarantis Group to Become Exclusive Distributor of Jordan in Greek Pharmacies

Sarantis Group announces that, following an agreement with Orkla Health AS, it will assume the exclusive distribution of Jordan products in Greek pharmacies as of February 1, 2026. The addition of Jordan to the Group’s portfolio represents a collaboration of strategic importance, further strengthening the Group’s presence in the Greek pharmacy channel and significantly expanding its footprint in the oral hygiene category.
More
Change cookies consent Revoke cookies consent